Multiple Myeloma: Clinical Updates from the American Society of Hematology Annual Meeting 2017

Publication date: Available online 1 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Evangelos Terpos The novel clinical data for myeloma that were presented in the 2017 Annual Meeting of the American Society of Hematology are summarized here. Studies with curative approach (CESAR) or prolonging progression-free survival (CENTAURUS) for high-risk smoldering multiple myeloma (SMM) patients are described. Updated data from large phase 3 studies for newly diagnosed MM (NDMM) patients who are eligible for autologous transplantation (ASCT; EMN02, MRC XI) are described along with the results of studies using novel anti-myeloma drug combinations for induction, consolidation and maintenance as first line therapy. The role of minimal residual disease for MM patients is also discussed. We also present the results of novel phase 3 studies in NDMM patients who are not eligible for ASCT (ALCYONE) and new data for their treatment. Recent updates of important studies in the field of relapsed/refractory MM (ASPIRE, POLLUX) along with novel immunotherapy approaches (anti-BCMA monoclonal antibodies, CART cells) are also reported. Finally, levofloxacin prophylaxis reduces febrile episodes and death events in NDMM, while two doses of high-dose influenza vaccine seem to maintain higher rates of seroprotection compared to those who received standard vaccination. All these data provide the basis for possible changes in the way we manage myeloma in the near future trying to â€...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research